Ro 48-5033: structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 6426755 |
| CHEMBL ID | 3901721 |
| SCHEMBL ID | 7205072 |
| MeSH ID | M0332079 |
| Synonym |
|---|
| n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-4-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide |
| 4-(2-hydroxy-1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-benzenesulfonamide |
| FT-0669430 |
| unii-vz7ynj87xh |
| ro 48-5033 |
| hydroxybosentan |
| ro 48-8634 |
| benzenesulfonamide, 4-(2-hydroxy-1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)- |
| vz7ynj87xh , |
| 253688-60-7 |
| hydroxy bosentan |
| bosentan metabolite ro 48-5033 |
| SCHEMBL7205072 |
| FAJQMBCLPZWTQJ-UHFFFAOYSA-N |
| n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]4-(2-hydroxy-1,1-dimethylethyl)benzenesulphonamide |
| n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]-4-(2-hydroxy-1,1-dimethylethyl)benzenesulphonamide |
| AKOS030239680 |
| J-015960 |
| CHEMBL3901721 |
| FT-0669431 |
| FT-0669432 |
| CS-0081840 |
| HY-121385 |
| BCP15832 |
| hydroxybosentan pound>>ro 48-5033 pound>>ro 48-8634 pound>>bosentan metabolite ro 48-5033 |
| 4-(2-hydroxy-1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)benzenesulfonamide |
| 4-(2-hydroxy-1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2?-bipyrimidin]-4-yl]-benzenesulfonamide |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1323162 | Drug level in human liver microsomes treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121ISSN: 1768-3254 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1323173 | Retention time of the compound | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121ISSN: 1768-3254 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1323149 | Drug level assessed as human recombinant CYP3A4-mediated compound formation treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121ISSN: 1768-3254 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1323171 | Drug level assessed as human recombinant CYP2C9-mediated compound formation treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121ISSN: 1768-3254 | Metabolism study and biological evaluation of bosentan derivatives. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| bosentan anhydrous | primary alcohol; pyrimidines; sulfonamide | antihypertensive agent; endothelin receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| bq 123 | cyclic peptide | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| ro 47-8634 | 2016 | 2016 | 8.0 | high | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute Liver Injury, Drug-Induced | 0 | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Bilateral Headache | 0 | 1999 | 1999 | 25.0 | medium | 1 | 0 | 1 | 0 | 0 | 0 | |
| Chemical and Drug Induced Liver Injury | 0 | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Cholera Infantum | 0 | 1999 | 1999 | 25.0 | medium | 1 | 0 | 1 | 0 | 0 | 0 | |
| Headache | 0 | 1999 | 1999 | 25.0 | medium | 1 | 0 | 1 | 0 | 0 | 0 |
| Article | Year |
|---|---|
| Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes. Drug metabolism and disposition: the biological fate of chemicals, , Volume: 44, Issue:1 | 2016 |
| Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. Journal of clinical pharmacology, , Volume: 39, Issue:7 | 1999 |
| Article | Year |
|---|---|
| Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. Journal of clinical pharmacology, , Volume: 45, Issue:1 | 2005 |
| Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. Journal of clinical pharmacology, , Volume: 39, Issue:7 | 1999 |
| Article | Year |
|---|---|
| Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. Journal of clinical pharmacology, , Volume: 39, Issue:7 | 1999 |